Kitakami, Japan

Naotake Konno

This inventor holds 1 USPTO granted patent. Top assignee: Euglena Co., Ltd.. Active years: 2017.


Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Naotake Konno: Innovator in Enzyme Technology

Introduction

Naotake Konno is a prominent inventor based in Kitakami, Japan. He has made significant contributions to the field of enzyme technology, particularly in the development of B-1,3-glucanase. His work has implications for various applications, including biotechnology and agriculture.

Latest Patents

Naotake Konno holds a patent for a B-1,3-glucanase, which includes a polynucleotide, recombinant vector, transformant, and a production method for the enzyme. This enzyme preparation is designed to decompose paramylon derived from specific genera. The B-1,3-glucanase exhibits hydrolyzing activity on the β-1,3-bond of β-1,3-glucan, with a substrate specificity that allows it to decompose at least paramylon. Notably, the enzyme demonstrates a decomposition activity ratio of 20% or higher when comparing paramylon to laminarin. The optimum pH for its activity ranges from 3.7 to 7.0, and it operates effectively at temperatures between 30-70°C.

Career Highlights

Naotake Konno is currently associated with Euglena Co., Ltd., where he continues to advance his research and development efforts. His innovative work in enzyme technology has positioned him as a key figure in the industry.

Collaborations

He collaborates with notable colleagues, including Kengo Suzuki and Ryo Arashida, who contribute to his research endeavors.

Conclusion

Naotake Konno's contributions to enzyme technology, particularly through his patent on B-1,3-glucanase, highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in biotechnology and related industries.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…